Provided by Tiger Trade Technology Pte. Ltd.

PTC Therapeutics

67.59
+1.942.96%
Volume:1.40M
Turnover:93.94M
Market Cap:5.64B
PE:-110.80
High:67.90
Open:65.99
Low:65.80
Close:65.65
52wk High:90.87
52wk Low:57.74
Shares:83.46M
Float Shares:73.65M
Volume Ratio:1.42
T/O Rate:1.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6100
EPS(LYR):7.78
ROE:-7740.12%
ROA:2.46%
PB:-34.11
PE(LYR):8.69

Loading ...

PTC Therapeutics Q2 EPS $0.92 Beats $0.23 Estimate, Sales $360.519M Beat $298.963M Estimate

Benzinga Earnings
·
Jul 31

PTC Therapeutics Q2 EPS USD 0.92

THOMSON REUTERS
·
Jul 31

PTC Therapeutics: Total Product Revenue Guidance Raised to $850 to $950 Million for FY 2026

THOMSON REUTERS
·
Jul 31

PTC Therapeutics Q2 Net Income USD 83.496 Million

THOMSON REUTERS
·
Jul 31

PTC Therapeutics' Phenylketonuria Physician Survey Yielded Mixed Results on Sephience Launch Momentum, RBC Says

MT Newswires Live
·
Jul 27

Earning Preview: PTC Therapeutics Q2 revenue is expected to increase by 74.33%, and institutional views are mostly bullish

Earnings Agent
·
Jul 24

Hamilton Lane Board Elects Michael Schmertzler as New Independent Director

THOMSON REUTERS
·
Jul 23

Barclays Remains a Buy on PTC Therapeutics (PTCT)

TIPRANKS
·
Jul 21

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Personalis (PSNL) and PTC Therapeutics (PTCT)

TIPRANKS
·
Jul 20

PTC Therapeutics is Maintained at Overweight by Wells Fargo

Dow Jones
·
Jul 20

PTC Therapeutics price target lowered to $93 from $95 at Wells Fargo

TIPRANKS
·
Jul 20

PTC Therapeutics Schedules Second-quarter 2026 Results Webcast Conference Call

Reuters
·
Jul 16

PTC Therapeutics is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
Jul 16

PTC Therapeutics price target raised to $130 from $124 at Cantor Fitzgerald

TIPRANKS
·
Jul 16

PTC Therapeutics price target raised to $95 from $93 at BofA

TIPRANKS
·
Jul 15

U.S. Research Roundup-equinix, Goldman Sachs, Jpmorgan

Reuters
·
Jul 15

PTC Therapeutics Director Mary L. Smith Disposes of USD 1.43 Million in Common Shares

Reuters
·
Jul 14

PTC Therapeutics EVP, CLO Mark Elliott Boulding Disposes of Common Shares Worth $257,864.88

Reuters
·
Jul 09

Barclays Remains a Buy on PTC Therapeutics (PTCT)

TIPRANKS
·
Jul 08

PTC Therapeutics is Maintained at Sector Perform by RBC Capital

Dow Jones
·
Jul 07